Media Summary: Hope Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, provides an overview of ... Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, discusses the final overall survival (OS) analysis of the Phase ... Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an overview of the rationale and trial design of the ...
Tropics 02 Sacituzumab Govetican Improves - Detailed Analysis & Overview
Hope Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, provides an overview of ... Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, discusses the final overall survival (OS) analysis of the Phase ... Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an overview of the rationale and trial design of the ... Arlene Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the recent press ... Scott Tagawa, MD, MS, Weill Cornell Medicine, New York City, NY, describes the randomized, Phase III Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an overview of a biomarker analysis of the Phase III ...
In patients with extensive stage small cell lung cancer (ES-SCLC), treatment options are limited following progression from ... Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, takes us through a study which evaluated the efficacy ... Dr Hope Rugo speaks to ecancer about the use of Prof Hope Rugo speaks to ecancer on the overall survival results from the phase III LBA76 - Overall survival (OS) results from the phase 3 Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors Dr Javier ...
